title: Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies.
abstract: Many small molecules and monoclonal antibodies blocking the activity of Epidermal Growth factor receptor (EGFR) have been developed and have shown clinical activity in patients with non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer (CRC), and are in clinical development for a range of other solid tumors. The toxicity profile of such agents is characterized by a typical pattern of cutaneous reactions. In this paper we reviewed the current available data regarding the clinical significance of skin reaction due to EGFR targeted agents. We show that skin toxicity can be considered as predictive marker of response to such drugs and that it is not disease specific; however its potential prognostic value is still to be proven.
authors: Oncology Deptartment, San Raffaele Scientific Institute, 60 Olgettina Street, 20132 Milan, Italy.
authors: Monica
authors: M
authors: Giovannini
authors: Vanesa
authors: V
authors: Gregorc
authors: Carmen
authors: C
authors: Belli
authors: Elisa
authors: E
authors: Roca
authors: Chiara
authors: C
authors: Lazzari
authors: Maria Grazia
authors: MG
authors: Viganò
authors: Anna
authors: A
authors: Serafico
authors: Eugenio
authors: E
authors: Villa